These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 35850866)

  • 21. Comparison of the diagnostic value of FDG-PET/CT and axillary ultrasound for the detection of lymph node metastases in breast cancer patients.
    Riegger C; Koeninger A; Hartung V; Otterbach F; Kimmig R; Forsting M; Bockisch A; Antoch G; Heusner TA
    Acta Radiol; 2012 Dec; 53(10):1092-8. PubMed ID: 23002144
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fluorodeoxyglucose positron emission tomography with sentinel lymph node biopsy for evaluation of axillary involvement in breast cancer.
    Gil-Rendo A; Zornoza G; García-Velloso MJ; Regueira FM; Beorlegui C; Cervera M
    Br J Surg; 2006 Jun; 93(6):707-12. PubMed ID: 16622900
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prediction of Extracapsular Invasion at Metastatic Sentinel Nodes and Non-sentinel Lymph Nodal Metastases by FDG-PET in Cases with Breast Cancer.
    Fujii T; Yajima R; Tatsuki H; Kuwano H
    Anticancer Res; 2016 Apr; 36(4):1785-9. PubMed ID: 27069160
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospective study of 2-[¹⁸F]fluorodeoxyglucose positron emission tomography in the assessment of regional nodal spread of disease in patients with breast cancer: an Ontario clinical oncology group study.
    Pritchard KI; Julian JA; Holloway CM; McCready D; Gulenchyn KY; George R; Hodgson N; Lovrics P; Perera F; Elavathil L; O'Malley FP; Down N; Bodurtha A; Shelley W; Levine MN
    J Clin Oncol; 2012 Apr; 30(12):1274-9. PubMed ID: 22393089
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic Performance of Noninvasive Imaging for Assessment of Axillary Response After Neoadjuvant Systemic Therapy in Clinically Node-positive Breast Cancer: A Systematic Review and Meta-analysis.
    Samiei S; de Mooij CM; Lobbes MBI; Keymeulen KBMI; van Nijnatten TJA; Smidt ML
    Ann Surg; 2021 Apr; 273(4):694-700. PubMed ID: 33201095
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A prospective comparative study of ultrasonography, contrast-enhanced MRI and 18F-FDG PET/CT for preoperative detection of axillary lymph node metastasis in breast cancer patients.
    Guney IB; Dalci K; Teke ZT; Kucuker KA
    Ann Ital Chir; 2020; 91():458-464. PubMed ID: 32213685
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Determinants of diagnostic performance of [F-18]fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer.
    van der Hoeven JJ; Hoekstra OS; Comans EF; Pijpers R; Boom RP; van Geldere D; Meijer S; Lammertsma AA; Teule GJ
    Ann Surg; 2002 Nov; 236(5):619-24. PubMed ID: 12409668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FDG PET positive lymph nodes are highly predictive of metastasis in breast cancer.
    Kumar R; Zhuang H; Schnall M; Conant E; Damia S; Weinstein S; Chandra P; Czerniecki B; Alavi A
    Nucl Med Commun; 2006 Mar; 27(3):231-6. PubMed ID: 16479242
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Implication of ¹⁸F-Fluorodeoxyglucose Uptake of Affected Axillary Lymph Nodes in Cases with Breast Cancer.
    Fujii T; Yajima R; Tatsuki H; Oosone K; Kuwano H
    Anticancer Res; 2016 Jan; 36(1):393-7. PubMed ID: 26722071
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Noninvasive nodal staging in patients with breast cancer using gadofosveset-enhanced magnetic resonance imaging: a feasibility study.
    Schipper RJ; Smidt ML; van Roozendaal LM; Castro CJ; de Vries B; Heuts EM; Keymeulen KB; Wildberger JE; Lobbes MB; Beets-Tan RG
    Invest Radiol; 2013 Mar; 48(3):134-9. PubMed ID: 23262788
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Locoregional lymph node involvement on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy.
    Koolen BB; Valdés Olmos RA; Elkhuizen PH; Vogel WV; Vrancken Peeters MJ; Rodenhuis S; Rutgers EJ
    Breast Cancer Res Treat; 2012 Aug; 135(1):231-40. PubMed ID: 22872522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of (18)F-FDG PET/CT in the diagnosis of breast cancer and lymph nodes metastases and micrometastases may be limited.
    Zhang X; Wu F; Han P
    Hell J Nucl Med; 2014; 17(3):177-83. PubMed ID: 25526754
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Routine use of standard breast MRI compared to axillary ultrasound for differentiating between no, limited and advanced axillary nodal disease in newly diagnosed breast cancer patients.
    van Nijnatten TJA; Ploumen EH; Schipper RJ; Goorts B; Andriessen EH; Vanwetswinkel S; Schavemaker M; Nelemans P; de Vries B; Beets-Tan RGH; Smidt ML; Lobbes MBI
    Eur J Radiol; 2016 Dec; 85(12):2288-2294. PubMed ID: 27842679
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of ultrasonography and FDG-PET in axillary lymph node staging of breast cancer.
    Ahn JH; Son EJ; Kim JA; Youk JH; Kim EK; Kwak JY; Ryu YH; Jeong J
    Acta Radiol; 2010 Oct; 51(8):859-65. PubMed ID: 20670083
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reliability of predicting low-burden (≤ 2) positive axillary lymph nodes indicating sentinel lymph node biopsy in primary operable breast cancer - a retrospective comparative study with PET/CT and breast MRI.
    Sae-Lim C; Wu WP; Chang MC; Lai HW; Chen ST; Chou CT; Liao CY; Huang HI; Chen ST; Chen DR; Hung CL
    World J Surg Oncol; 2024 Jan; 22(1):12. PubMed ID: 38183069
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FDG PET evaluation of early axillary lymph node response to neoadjuvant chemotherapy in stage II and III breast cancer patients.
    Rousseau C; Devillers A; Campone M; Campion L; Ferrer L; Sagan C; Ricaud M; Bridji B; Kraeber-Bodéré F
    Eur J Nucl Med Mol Imaging; 2011 Jun; 38(6):1029-36. PubMed ID: 21308372
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Investigation of 18F-FDG PET in the selection of patients with breast cancer as candidates for sentinel node biopsy after neoadjuvant therapy.
    Gilardi L; De Cicco C; Colleoni M; Cardillo A; Montagna E; Dellapasqua S; Galimberti V; Bagnardi V; Paganelli G
    Eur J Nucl Med Mol Imaging; 2010 Oct; 37(10):1834-41. PubMed ID: 20533032
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Determination of indication for sentinel lymph node biopsy in clinical node-negative breast cancer using preoperative 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging.
    Taira N; Ohsumi S; Takabatake D; Hara F; Takashima S; Aogi K; Takashima S; Inoue T; Sugata S; Nishimura R
    Jpn J Clin Oncol; 2009 Jan; 39(1):16-21. PubMed ID: 18997183
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the Performance of [
    Han S; Huang Y
    Curr Med Imaging; 2024; 20():e15734056304849. PubMed ID: 38988163
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selective Sentinel Node Plus Additional Non-Sentinel Node Biopsy Based on an FDG-PET/CT Scan in Early Breast Cancer Patients: Single Institutional Experience.
    Kim J; Lee J; Chang E; Kim S; Suh K; Sul J; Song I; Kim Y; Lee C
    World J Surg; 2009 May; 33(5):943-9. PubMed ID: 19259728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.